Immune response against SARS-CoV-2 in pediatric patients including young infants

Yoshiki Kawamura1, Yuki Higashimoto2, Hiroki Miura1

  • 1Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan.

Journal of Medical Virology
|September 8, 2020
PubMed

Insights

Young infants and children can develop an immune response to SARS-CoV-2, the virus causing COVID-19, even if asymptomatic. Isolation is recommended for SARS-CoV-2 negative children from infected parents when feasible.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Immunology

Background:

  • COVID-19 in children is typically mild or asymptomatic.
  • Limited data exists on clinical and virological features in pediatric COVID-19, especially infants.
  • Understanding pediatric immune responses to SARS-CoV-2 is crucial.

Purpose of the Study:

  • To investigate the clinical and virological characteristics of pediatric COVID-19 cases.
  • To assess immune response (seroconversion) in young children exposed to SARS-CoV-2.
  • To provide insights into managing pediatric COVID-19 cases within families.

Main Methods:

  • Case study of four pediatric patients, including two infants, with COVID-19.
  • Virological examination and serological testing for SARS-CoV-2.
  • Clinical observation and assessment of exposure history.

Main Results:

  • Asymptomatic SARS-CoV-2 infection and seroconversion observed in one- and four-month-old infants.
  • A three-year-old exposed to a COVID-19-positive father seroconverted despite being initially negative.
  • An eleven-year-old sibling, isolated from the infected father, did not seroconvert.

Conclusions:

  • Young infants can mount an immune response to SARS-CoV-2.
  • Isolation of SARS-CoV-2 negative children from infected parents is advised when possible.
  • Caregiver situations require individualized management strategies for pediatric COVID-19 cases.

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
612
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
139
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
145
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
168